# Sodium-glucose Co-transporter 2 Inhibitors Effects in Failing Heart Patients

Study · id `cardio:ct-nct03977116` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03977116](<https://clinicaltrials.gov/study/NCT03977116>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03977116

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT03977116. Randomized; single masking; primary purpose prevention. Start 2017-01-01 (actual); primary completion 2019-01-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT03977116, source copy `cardio:ctgov-nct03977116-2020-03-03`, retrieved 2026-10-26)
- Started: 2017-01-01 (actual) (ClinicalTrials.gov record NCT03977116, source copy `cardio:ctgov-nct03977116-2020-03-03`, retrieved 2026-10-26)
- Primary completion: 2019-01-01 (actual) (ClinicalTrials.gov record NCT03977116, source copy `cardio:ctgov-nct03977116-2020-03-03`, retrieved 2026-10-26)
- Completion: 2019-03-01 (actual) (ClinicalTrials.gov record NCT03977116, source copy `cardio:ctgov-nct03977116-2020-03-03`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT03977116, source copy `cardio:ctgov-nct03977116-2020-03-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03977116-2020-03-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Sodium-glucose Co-transporter 2 Inhibitors Effects in Failing Heart Patients
- Condition: Diabetes Mellitus
- Condition: Heart Failure
- Condition: Ventricular Arrythmia
- Intervention (Drug): SLGT2
- Intervention (Drug): Placebo
- Lead sponsor: University of Campania Luigi Vanvitelli
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Campania Luigi Vanvitelli (`cardio:org-university-of-campania-luigi-vanvitelli`)

## Provenance

Content hash: 0880fd4c984e7f9e907352b49f587322ec2622af1b55765c2a81f475ac8e3846
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
